title: [Value of Clodronate in the treatment of bone metastasis].
abstract: The intravenous administration of Clodronate, a strong inhibitor of osteoclastic activity provides a safe and very effective treatment of hypercalcemia whether secondary to bone metastasis or due to paraneoplastic syndrome. Its action is fast, exclusively osseous and lasts up to 7 days. The response is incomplete when increased renal absorption is the predominant mechanism of hypercalcemia. The data published by Elomaa et al on osteolytic metastases in breast cancer patients show a significant improvement with regard to pain reduction, prevention of fractures as well as hypercalcemia. The results obtained using a 1-yr oral treatment need further confirmation.
authors.affiliation: Service de médecine oncologique, Institut Curie, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
mesh_terms: D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D001842:Bone and Bones / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology; D004002:Clodronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010014:Osteolysis / Q000188:drug therapy / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology
chemical_list: D004002:Clodronic Acid
vernacular_title: Intérêt du Clodronate dans le traitement des métastases osseuses.